

Title (en)  
VALSARTAN SALTS

Title (de)  
VALSARTAN SALZE

Title (fr)  
SELS DE VALSARTAN

Publication  
**EP 1313714 B1 20080827 (EN)**

Application  
**EP 01969407 A 20010717**

Priority  
• EP 01969407 A 20010717  
• EP 0108253 W 20010717  
• EP 00115556 A 20000719

Abstract (en)  
[origin: WO0206253A1] The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.

IPC 8 full level  
**C07D 257/04** (2006.01); **A61K 31/41** (2006.01); **A61K 45/00** (2006.01); **A61P 3/04** (2006.01); **A61P 3/06** (2006.01); **A61P 3/10** (2006.01); **A61P 9/00** (2006.01); **A61P 9/04** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 13/02** (2006.01); **A61P 13/12** (2006.01); **A61P 27/06** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP KR US)  
**A61K 31/41** (2013.01 - EP US); **A61K 45/06** (2013.01 - US); **A61P 3/04** (2018.01 - EP); **A61P 3/06** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 7/10** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/04** (2018.01 - EP); **A61P 9/08** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 9/12** (2018.01 - EP); **A61P 13/02** (2018.01 - EP); **A61P 13/12** (2018.01 - EP); **A61P 27/06** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07D 257/04** (2013.01 - EP KR US)

C-Set (source: EP US)  
1. **A61K 31/41 + A61K 31/00**  
2. **A61K 31/41 + A61K 2300/00**

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)  
RO SI

DOCDB simple family (publication)  
**WO 0206253 A1 20020124**; AR 032758 A1 20031126; AR 069374 A2 20100120; AT E406355 T1 20080915; AU 2001289672 B2 20051208; AU 8967201 A 20020130; BR 0112665 A 20030624; CA 2415962 A1 20020124; CA 2415962 C 20100706; CN 100413852 C 20080827; CN 1216873 C 20050831; CN 1443176 A 20030917; CN 1680341 A 20051012; CY 1108559 T1 20140409; CZ 2003117 A3 20030514; CZ 303389 B6 20120829; DE 60135560 D1 20081009; DK 1313714 T3 20081215; EC SP034436 A 20030310; EP 1313714 A1 20030528; EP 1313714 B1 20080827; ES 2309090 T3 20081216; HK 1055963 A1 20040130; HU 229280 B1 20131028; HU P0300731 A2 20030929; HU P0300731 A3 20060529; IL 153882 A0 20030731; IL 153882 A 20090901; JP 2004504307 A 20040212; JP 4102664 B2 20080618; KR 100529658 B1 20051121; KR 20030015888 A 20030225; MX PA03000525 A 20030514; MY 136446 A 20081031; MY 152846 A 20141128; NO 20030232 D0 20030117; NO 20030232 L 20030117; NO 326504 B1 20081215; NZ 523557 A 20041224; PE 20020613 A1 20020807; PL 205715 B1 20100531; PL 360737 A1 20040920; PT 1313714 E 20081103; RU 2275363 C2 20060427; SI 1313714 T1 20090228; SK 287558 B6 20110204; SK 552003 A3 20030701; US 2003207930 A1 20031106; US 2007149587 A1 20070628; US 2008293791 A1 20081127; US 2012329844 A1 20121227; US 2014073677 A1 20140313; US 8278339 B2 20121002; US 9499499 B2 20161122; ZA 200300285 B 20040325

DOCDB simple family (application)  
**EP 0108253 W 20010717**; AR P010103417 A 20010717; AR P080105034 A 20081119; AT 01969407 T 20010717; AU 2001289672 A 20010717; AU 8967201 A 20010717; BR 0112665 A 20010717; CA 2415962 A 20010717; CN 01813039 A 20010717; CN 200510007707 A 20010717; CY 081101215 T 20081027; CZ 2003117 A 20010717; DE 60135560 T 20010717; DK 01969407 T 20010717; EC SP034436 A 20030117; EP 01969407 A 20010717; ES 01969407 T 20010717; HK 03108267 A 20031113; HU P0300731 A 20010717; IL 15388201 A 20010717; IL 15388203 A 20030109; JP 2002512157 A 20010717; KR 20037000815 A 20030118; MX PA03000525 A 20010717; MY PI20013368 A 20010717; MY PI20064483 A 20010717; NO 20030232 A 20030117; NZ 52355701 A 20010717; PE 2001000723 A 20010717; PL 36073701 A 20010717; PT 01969407 T 20010717; RU 2003104789 A 20010717; SI 200130881 T 20010717; SK 552003 A 20010717; US 18617208 A 20080805; US 201213599032 A 20120830; US 201314081441 A 20131115; US 33310003 A 20030224; US 67828407 A 20070223; ZA 200300285 A 20030110